Total Payments
$3,618
2022 Payments
$350.00
Companies
15
Transactions
30
Medicare Patients
115
Medicare Billing
$6,734
Payment Breakdown by Category
Research$2,787 (77.0%)
Food & Beverage$510.09 (14.1%)
Other$321.00 (8.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2,787 | 8 | 77.0% |
| Food and Beverage | $510.09 | 21 | 14.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $321.00 | 1 | 8.9% |
Payments by Type
Research
$2,787
8 transactions
General
$831.09
22 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $2,437 | 7 | $0 (2017) |
| Anika Therapeutics, Inc. | $350.00 | 1 | $0 (2022) |
| Pacira Pharmaceuticals Incorporated | $321.00 | 1 | $0 (2020) |
| ENCORE MEDICAL, LP | $126.63 | 1 | $0 (2017) |
| Amgen Inc. | $107.42 | 5 | $0 (2020) |
| Mallinckrodt Enterprises LLC | $67.18 | 3 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $53.36 | 3 | $0 (2019) |
| Mallinckrodt Hospital Products Inc. | $33.96 | 1 | $0 (2020) |
| Iroko Pharmaceuticals, LLC | $29.86 | 2 | $0 (2018) |
| UCB, Inc. | $21.24 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $350.00 | 1 | Anika Therapeutics, Inc. ($350.00) |
| 2020 | $395.49 | 4 | Pacira Pharmaceuticals Incorporated ($321.00) |
| 2019 | $155.30 | 7 | Amgen Inc. ($68.30) |
| 2018 | $50.72 | 3 | Amgen Inc. ($19.83) |
| 2017 | $2,666 | 15 | Regeneron Pharmaceuticals, Inc. ($2,437) |
All Payment Transactions
30 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/05/2022 | Anika Therapeutics, Inc. | — | — | Cash or cash equivalent | $350.00 | Research |
| Study: A Prospective, Randomized, Active Treatment-controlled, Evaluator-blinded Multicenter Study to Establish the Superiority of Hyalofast With BMAC in the Treatment of Articular Knee Cartilage Defect Lesions in Comparison to Control | ||||||
| 10/13/2020 | Pacira Pharmaceuticals Incorporated | EXPAREL (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $321.00 | General |
| Category: PAIN MANAGEMENT | ||||||
| 06/23/2020 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $33.96 | General |
| Category: IMMUNOLOGY | ||||||
| 04/14/2020 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $19.29 | General |
| Category: Inflammation | ||||||
| 02/27/2020 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $21.24 | General |
| Category: Immunology | ||||||
| 11/25/2019 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $15.49 | General |
| Category: Bone Health | ||||||
| 09/11/2019 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $22.97 | General |
| Category: Bone Health | ||||||
| 08/09/2019 | Mallinckrodt Enterprises LLC | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $22.37 | General |
| Category: AUTOIMMUNE AND RARE DISEASE | ||||||
| 08/01/2019 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $29.84 | General |
| Category: Bone Health | ||||||
| 06/12/2019 | ARBOR PHARMACEUTICALS, INC. | Horizant (Drug) | Food and Beverage | In-kind items and services | $13.54 | General |
| Category: Sleep | ||||||
| 05/01/2019 | Mallinckrodt Enterprises LLC | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $30.76 | General |
| Category: AUTOIMMUNE AND RARE DISEASE | ||||||
| 04/02/2019 | SANOFI-AVENTIS U.S. LLC | SYNVISC-ONE (Device) | Food and Beverage | In-kind items and services | $20.33 | General |
| Category: OSTEOARTHRITIS | ||||||
| 07/26/2018 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $19.83 | General |
| Category: Inflammation | ||||||
| 06/27/2018 | Iroko Pharmaceuticals, LLC | VIVLODEX (Drug), TIVORBEX, ZORVOLEX | Food and Beverage | In-kind items and services | $15.59 | General |
| Category: NSAID | ||||||
| 01/03/2018 | SANOFI-AVENTIS U.S. LLC | SYNVISC-ONE (Device) | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: OSTEOARTHRITIS | ||||||
| 11/09/2017 | ENCORE MEDICAL, LP | DJO Surgical TaperFill Hip System (Device) | Food and Beverage | In-kind items and services | $126.63 | General |
| Category: Joint Implants | ||||||
| 07/12/2017 | SANOFI-AVENTIS U.S. LLC | SYNVISC-ONE (Device) | Food and Beverage | In-kind items and services | $17.73 | General |
| Category: OSTEOARTHRITIS | ||||||
| 06/24/2017 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $684.40 | Research |
| Study: A Phase 3 Randomized, Double-blind, Multi-dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip | ||||||
| 06/23/2017 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $276.59 | Research |
| Study: A Phase 3 Randomized, Double-blind, Multi-dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip | ||||||
| 06/23/2017 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $130.87 | Research |
| Study: A Phase 3 Randomized, Double-blind, Multi-dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip | ||||||
| 06/23/2017 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $92.94 | Research |
| Study: A Phase 3 Randomized, Double-blind, Multi-dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip | ||||||
| 06/23/2017 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $59.81 | Research |
| Study: A Phase 3 Randomized, Double-blind, Multi-dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip | ||||||
| 06/22/2017 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $221.59 | Research |
| Study: A Phase 3 Randomized, Double-blind, Multi-dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip | ||||||
| 06/15/2017 | Iroko Pharmaceuticals, LLC | VIVLODEX (Drug), TIVORBEX, ZORVOLEX | Food and Beverage | In-kind items and services | $14.27 | General |
| Category: NSAID | ||||||
| 06/07/2017 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $970.57 | Research |
| Study: A Phase 3 Randomized, Double-blind, Multi-dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Multi-dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip | Regeneron Pharmaceuticals, Inc. | $2,437 | 7 |
| A Prospective, Randomized, Active Treatment-controlled, Evaluator-blinded Multicenter Study to Establish the Superiority of Hyalofast With BMAC in the Treatment of Articular Knee Cartilage Defect Lesions in Comparison to Control | Anika Therapeutics, Inc. | $350.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 5 | 115 | 129 | $27,174 | $6,734 |
Total Patients
115
Total Services
129
Medicare Billing
$6,734
Procedure Codes
5
All Medicare Procedures & Services
5 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 38 | 44 | $10,340 | $2,954 | 28.6% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 20 | 20 | $7,180 | $1,363 | 19.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 23 | 26 | $4,082 | $1,082 | 26.5% |
| 20610 | Aspiration and/or injection of large joint or joint capsule | Office | 2020 | 17 | 22 | $3,872 | $886.57 | 22.9% |
| 73564 | X-ray of knee, 4 or more views | Office | 2020 | 17 | 17 | $1,700 | $447.99 | 26.4% |
About Dr. Louis Levy, MD
Dr. Louis Levy, MD is a Specialist healthcare provider based in La Mesa, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/20/2005. The National Provider Identifier (NPI) number assigned to this provider is 1225037336.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Louis Levy, MD has received a total of $3,618 in payments from pharmaceutical and medical device companies, with $350.00 received in 2022. These payments were reported across 30 transactions from 15 companies. The most common payment nature is "" ($2,787).
As a Medicare-enrolled provider, Levy has provided services to 115 Medicare beneficiaries, totaling 129 services with total Medicare billing of $6,734. Data is available for 1 year (2020–2020), covering 5 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location La Mesa, CA
- Active Since 07/20/2005
- Last Updated 07/09/2007
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1225037336
Products in Payments
- EXPAREL (Drug) $321.00
- DJO Surgical TaperFill Hip System (Device) $126.63
- ACTHAR (Biological) $87.09
- EVENITY (Biological) $68.30
- SYNVISC-ONE (Device) $53.36
- Enbrel (Biological) $39.12
- VIVLODEX (Drug) $29.86
- Cimzia (Drug) $21.24
- CONTRAVE (Drug) $14.99
- Triathlon (Device) $14.54
- ZNN (Device) $14.37
- OFIRMEV (Drug) $14.05
- Horizant (Drug) $13.54
- Ascend Flex (Device) $13.00
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in La Mesa
Dr. Scott Hacker, M.d, M.D
Specialist — Payments: $1.1M
Specialist $1.1M
Dr. Venu Prabaker, M.d, M.D
Specialist — Payments: $24,397
Specialist $24,397
Dr. Sathya Pokala, M.d, M.D
Specialist — Payments: $16,738
Specialist $16,738
Kelly Dewitt, Md, MD
Specialist — Payments: $4,552
Specialist $4,552
Afsaneh Nourin, M.d, M.D
Specialist — Payments: $1,189
Specialist $1,189
Bruce Haight, M.d., Inc, M.D., INC
Specialist — Payments: $674.76
Specialist $674.76